Table 4 Overall survival and progression-free survival from the start of second-line targeted therapy according to MSKCC and IMDC risk groups (patients with evaluable MSKCC score, n = 1029; patients with evaluable IMDC score, n = 540)
Prognostic score | n | Median OS (months) (95% CI) | Median PFS (months) (95% CI) |
|---|---|---|---|
IMDC good | 178 | 20.2 (13.6–26.8) | 6.9 (5.0–8.8) |
IMDC intermediate | 314 | 17.0 (13.1–20.9) | 5.8 (5.1–6.5) |
IMDC poor | 48 | 11.5 (5.3–17.7) | 3.7 (2.8–4.6) |
MSKCC good | 378 | 19.2 (16.3–22.0) | 7.3 (6.1–8.6) |
MSKCC intermediate | 596 | 15.7 (13.5–17.9) | 6.0 (5.4–6.5) |
MSKCC poor | 55 | 5.5 (3.1–7.8) | 3.7 (3.0–4.3) |